Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection.

ABSTRACT: Several chronic respiratory diseases are characterized by recurrent and/or persistent infections, chronic inflammatory responses and tissue remodeling, including increased levels of glycosaminoglycans which are known structural components of the airways. Among glycosaminoglycans, heparan sulfate (HS) has been suggested to contribute to excessive inflammatory responses. Here, we aim at (i) investigating whether long-term infection by Pseudomonas aeruginosa, one of the most worrisome threat in chronic respiratory diseases, may impact HS levels, and (ii) exploring HS competitors as potential anti-inflammatory drugs during P. aeruginosa pneumonia. P. aeruginosa clinical strains and ad-hoc synthesized HS competitors were used in vitro and in murine models of lung infection.

SUBMITTER: Lore NI 

PROVIDER: S-EPMC5796156 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature